Floatz logo

Durvalumab

Early-stage

MedImmune LLCmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Early-stage cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN MONOCLONAL MEDI9447 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI9447 .LAMBDA.-CHAIN, DIMER
MedImmune LLC
Phase 2B
Ibrutinib
MedImmune LLC
Phase 2B
Monalizumab
MedImmune LLC
Phase 2B
Danvatirsen
MedImmune LLC
Phase 2B
PEGASPARGASE
Chinese Academy of Medical Sciences
Phase 2CCC
Eloxatin
Chinese Academy of Medical Sciences
Phase 2CCC

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →